Judy Lieberman | GenomeWeb

Judy Lieberman

Premium

Alnylam Pharmaceuticals has named Judy Lieberman, a senior investigator at the CBR Institute for Biomedical Research and a professor at Harvard Medical School, to its scientific advisory board.

The appointment comes a little more than a month after Alnylam licensed delivery technology developed by Lieberman from Harvard.

Lieberman holds a PhD in physics from Rockefeller University and an MD from the joint Harvard-Massachusetts Institute of Technology program in health, science, and technology.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.